UBS Asset Management Americas Inc. lifted its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 93.5% in the fourth quarter, Holdings Channel reports. The fund owned 553,501 shares of the biopharmaceutical company’s stock after acquiring an additional 267,442 shares during the quarter. UBS Asset Management Americas Inc.’s holdings in Regeneron Pharmaceuticals were worth $208,094,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Harding Loevner LP raised its position in Regeneron Pharmaceuticals by 589.2% in the 3rd quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock worth $286,619,000 after purchasing an additional 3,131,966 shares during the period. Polen Capital Management LLC raised its position in Regeneron Pharmaceuticals by 1.2% in the 4th quarter. Polen Capital Management LLC now owns 1,389,545 shares of the biopharmaceutical company’s stock worth $522,413,000 after purchasing an additional 15,931 shares during the period. American Century Companies Inc. raised its position in Regeneron Pharmaceuticals by 2.3% in the 3rd quarter. American Century Companies Inc. now owns 917,554 shares of the biopharmaceutical company’s stock worth $410,257,000 after purchasing an additional 20,218 shares during the period. Orbimed Advisors LLC raised its position in Regeneron Pharmaceuticals by 22.7% in the 3rd quarter. Orbimed Advisors LLC now owns 572,770 shares of the biopharmaceutical company’s stock worth $256,097,000 after purchasing an additional 106,000 shares during the period. Finally, Legal & General Group Plc raised its position in Regeneron Pharmaceuticals by 0.7% in the 3rd quarter. Legal & General Group Plc now owns 371,110 shares of the biopharmaceutical company’s stock worth $165,929,000 after purchasing an additional 2,729 shares during the period. 65.89% of the stock is owned by institutional investors.
A number of equities analysts recently commented on REGN shares. JPMorgan Chase & Co. lifted their target price on shares of Regeneron Pharmaceuticals from $455.00 to $457.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 24th. Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 5th. Canaccord Genuity reiterated a “buy” rating and issued a $522.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 7th. Evercore ISI decreased their target price on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating on the stock in a research report on Thursday, November 16th. Finally, Guggenheim set a $530.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 9th. Three equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $457.03.
Shares of Regeneron Pharmaceuticals Inc (REGN) opened at $332.15 on Friday. The firm has a market cap of $35,685.86, a PE ratio of 24.03, a PEG ratio of 1.04 and a beta of 1.47. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.18 and a current ratio of 3.82. Regeneron Pharmaceuticals Inc has a 52 week low of $313.53 and a 52 week high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $1.05. The firm had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The company’s revenue for the quarter was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.04 EPS. sell-side analysts forecast that Regeneron Pharmaceuticals Inc will post 19.2 earnings per share for the current fiscal year.
In other news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.80% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Regeneron Pharmaceuticals Inc (REGN) Shares Bought by UBS Asset Management Americas Inc.” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/02/18/regeneron-pharmaceuticals-inc-regn-shares-bought-by-ubs-asset-management-americas-inc.html.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.